Form 8-K

8-K — GE HealthCare Technologies Inc.

Accession: 0001932393-26-000047

Filed: 2026-07-29

Period: 2026-07-29

CIK: 0001932393

SIC: 3844 (X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — gehc-20260729.htm (Primary)

EX-99 (gehcex99ais.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: gehc-20260729.htm · Sequence: 1

gehc-20260729

0001932393false00019323932026-07-292026-07-29

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 29, 2026

GE HEALTHCARE TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

Delaware 001-41528 88-2515116

(State or other jurisdiction

of incorporation) (Commission

File Number) (IRS Employer

Identification No.)

500 W. Monroe Street, Chicago, IL

60661

(Address of principal executive offices) (Zip Code)

(Registrant’s telephone number, including area code) (833) 735-1139

______________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.01 per share

GEHC

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

GE HealthCare Technologies Inc. ("GE HealthCare," the “Company,” “our,” “us,” or “we”) is filing this Current Report on Form 8-K to provide recast unaudited historical financial information related to a previously announced change in reportable segments. In the second quarter of 2026, we made a strategic change to our executive leadership and to our segments, combining our Imaging and Advanced Visualization Solutions businesses into a new operating and reportable segment, Advanced Imaging Solutions (“AIS”). This change positions the Company to enhance execution, accelerate innovation, and create efficiencies.

Following this organizational change, the Company has three reportable segments: AIS, Pharmaceutical Diagnostics (“PDx”), and Patient Care Solutions (“PCS”), which is aligned with how the Chief Operating Decision Maker reviews the business for the purpose of assessing performance and allocating resources. These segments have been identified based on the nature of the products sold and how the Company manages its operations. We have not aggregated any of our operating segments to form reportable segments. Our PDx and PCS reportable segments operate as described in the “Business” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

ADVANCED IMAGING SOLUTIONS.

Our AIS segment provides diagnostic, interventional, and digital imaging technologies designed to support clinical decision-making across the care continuum, from screening and diagnosis through treatment and follow-up. The AIS segment has a product portfolio that serves customers across three core areas: Radiology, Specialized Ultrasound, and Procedural Guidance. Radiology was formerly reported as our Imaging business, while Specialized Ultrasound and Procedural Guidance were previously reported in our AVS business. Our products support providers in the delivery of care for a broad spectrum of clinical specialties, including oncology, cardiology, neurology, nuclear medicine, orthopedics, women’s health, pediatrics, and surgery.

Radiology includes the following product lines.

•Computed Tomography (“CT”) scans render 3D anatomical images of structures, such as bone, soft tissue, and air cavities using an X-ray tube that rotates around a patient. The images are used in a wide variety of applications, including the detection of tumors or lesions, blocked blood vessels in the brain, abnormal heart conditions, complex bone fractures, and internal injuries from trauma. Our comprehensive CT portfolio includes multi-purpose and specialty scanners.

•Magnetic Resonance (“MR”) is a non-invasive imaging technology that produces detailed anatomical images of almost every internal structure in the human body, such as the brain, spinal cord, heart, breast, kidneys, muscles, ligaments, and tendons. MR can also be used for functional imaging, and it is well-suited for disease detection, diagnosis, and treatment monitoring of a variety of conditions, including stroke, cancer, trauma, aneurysm, multiple sclerosis, cardiomyopathy, and congenital disorders. Our MR portfolio includes scanners for a range of clinical capabilities through different bore sizes, magnetic field strengths, and scalable platforms.

•Molecular Imaging (“MI”) enables the visualization, characterization, and quantification of functional processes taking place at the cellular and subcellular levels within patients. The images produced by MI systems allow clinicians to study the cellular and molecular pathways and mechanisms of disease in patients. We offer a complete MI solution from cyclotrons, chemistry synthesis, positron emission tomography (“PET”), CT, single-photon emission computed tomography, PET/MR, and nuclear medicine to advanced digital and AI-enabled solutions. Our MI team works closely with the PDx segment and their innovations and collaborations with pharmaceutical companies.

•Solutions for Enterprise Imaging provides a portfolio of cloud-enabled, AI-powered software that enables healthcare organizations to capture, manage, and integrate medical imaging and related clinical data across the enterprise. These solutions support radiology, cardiology, and other imaging specialties by streamlining workflows, improving clinician productivity, and enhancing care coordination across hospital, outpatient, and ambulatory settings. The portfolio is designed to evolve over time through software upgrades and new capabilities, helping customers address workforce challenges and improve patient outcomes.

•Women’s Health products use X-ray technology to help clinicians screen for and diagnose breast cancer as well as bone and metabolic diseases in women. The product portfolio includes imaging and biopsy positioning systems designed to image the breast and dual energy X-ray absorptiometry scanners designed to image bones with low mineral density.

•X-ray systems are used by clinicians to perform first-line diagnostic imaging examinations of anatomical structures in the body, such as bones, lungs, and the gastrointestinal tract. Our X-ray product portfolio includes systems for three distinct clinical situations: fixed room radiography products installed in hospitals and imaging centers; mobile radiography products used for bedside or other point-of-care imaging needs; and fluoroscopy products installed in hospitals for dynamic or “moving” X-ray imaging in applications like gastrointestinal examinations.

Procedural Guidance includes the following product lines.

•CardioVascular and Interventional Solutions provides clinicians with innovative solutions that enhance diagnoses, intervention, treatment, and monitoring in therapeutic areas such as cardiology in the catheterization labs, peripheral vascular, neurovascular, interventional radiology, and oncology. Our integrated portfolio of ultrasound systems for assessing cardiac structure and function, alongside advanced real-time X-ray imaging systems, combines innovative imaging technology, intelligent workflows, and ergonomic design to help healthcare providers deliver care with greater confidence and efficiency. Together, these solutions support image-guided therapy across the full spectrum of interventional procedures.

•Surgical Innovations products are used in the procedural environment and include a broad portfolio of advanced mobile surgical C-arms that meet clinical needs for surgical imaging and are designed to be easily maneuverable in operating rooms and adaptable for various surgical procedures. Surgical visualization and guidance technology expands the use of ultrasound beyond diagnostics to provide real-time information during procedures to help guide interventions and navigate inside the human body.

Specialized Ultrasound includes the following product lines.

•Comprehensive Care Ultrasound includes systems that produce images to support precise screening, diagnosis, monitoring, and treatment across the whole body, including liver, thyroid, kidney, breast, vascular, and transcranial applications. These systems include point-of-care and handheld ultrasound devices to support clinical decision-making throughout various care pathways in diverse sites of care. Our systems combine high image quality with comprehensive clinical tools including measurement quantification, workflow automation, cross-modality networking, real-time and AI-enabled scan guidance, and cloud-based technologies with versatility, accessibility, and portability required to deliver care.

•Women’s Health Ultrasound provides systems to support obstetrics, gynecology, and reproductive medicine. These care areas require specially designed ultrasound products that account for patient comfort and workflow constraints to enable practitioners to provide higher-quality screening, exams, and procedural care, and give clinicians images with the clarity and definition they need to focus on early detection and intervention.

Exhibit 99, attached hereto, presents supplemental recast unaudited financial information reflecting the Company’s new reportable segment structure. This recast financial information is being provided to aid in comparability and has no impact on previously reported financial statements for any period.

The information furnished pursuant to Item 7.01, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Description

Recast unaudited historical financial information reflecting the Company’s new reportable segment structure

104 The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GE HealthCare Technologies Inc.

(Registrant)

Date: July 29, 2026

/s/ George A. Newcomb

George A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)

EX-99

Filename: gehcex99ais.htm · Sequence: 2

Document

Exhibit 99

GE HealthCare

Recast Unaudited Historical Financial Information Reflecting the Company’s New Reportable Segment Structure

In the second quarter of 2026, we made a strategic change to our executive leadership and to our segments, combining our Imaging and Advanced Visualization Solutions businesses into a new operating and reportable segment, Advanced Imaging Solutions (“AIS”). This change positions the Company to enhance execution, accelerate innovation, and create efficiencies.

ADVANCED IMAGING SOLUTIONS.

Radiology includes the following product lines.

Procedural Guidance includes the following product lines.

Specialized Ultrasound includes the following product lines.

Tables throughout this document are presented in millions of U.S. dollars unless otherwise stated and certain columns and rows may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts.

The tables below reflect our unaudited historical financial results recast to conform to the new segment structure.

Total Revenues by Segment For the three months ended

Unaudited

March 31, 2026

AIS:

Radiology $ 2,299

Procedural Guidance 719

Specialized Ultrasound 622

Total AIS 3,640

Total PDx 770

PCS:

Monitoring Solutions 519

Life Support Solutions 185

Total PCS 704

Other(1)

Total revenues $ 5,131

(1) Financial information not presented within the reportable segments, shown within the Other category, represents HealthCare Financial Services (“HFS”), which does not meet the definition of an operating segment.

Total Revenues by Segment For the three months ended For the year ended

Unaudited

March 31, 2025 June 30, 2025 September 30, 2025 December 31, 2025 December 31, 2025

AIS:

Radiology $ 2,140 $ 2,204 $ 2,349 $ 2,552 $ 9,245

Procedural Guidance 641 660 662 789 2,752

Specialized Ultrasound 598 630 638 735 2,601

Total AIS 3,379 3,493 3,649 4,077 14,599

Total PDx 632 729 749 790 2,900

PCS:

Monitoring Solutions 556 578 544 577 2,256

Life Support Solutions 197 200 187 247 831

Total PCS 753 778 731 825 3,086

Other(1)

13 6 15 7 40

Total revenues $ 4,777 $ 5,007 $ 5,143 $ 5,698 $ 20,625

(1) Financial information not presented within the reportable segments, shown within the Other category, represents HFS, which does not meet the definition of an operating segment.

Total Revenues by Segment For the three months ended For the year ended

Unaudited March 31, 2024 June 30, 2024 September 30, 2024 December 31, 2024 December 31, 2024

AIS:

Radiology $ 2,062 $ 2,171 $ 2,229 $ 2,393 $ 8,855

Procedural Guidance 651 668 647 744 2,711

Specialized Ultrasound 576 581 569 696 2,420

Total AIS 3,289 3,419 3,445 3,833 13,986

Total PDx 599 639 625 646 2,508

PCS:

Monitoring Solutions 527 538 556 574 2,194

Life Support Solutions 220 235 223 253 931

Total PCS 747 772 779 827 3,125

Other(1)

15 9 15 13 52

Total revenues $ 4,650 $ 4,839 $ 4,863 $ 5,319 $ 19,672

(1) Financial information not presented within the reportable segments, shown within the Other category, represents HFS, which does not meet the definition of an operating segment.

Significant Expenses by Segment For the three months ended

March 31, 2026

AIS:

Cost of sales $ 2,204

Other segment items(1)

957

Total AIS

$ 3,161

PDx:

Cost of sales $ 406

Other segment items(1)

167

Total PDx $ 573

PCS:

Cost of sales $ 481

Other segment items(1)

213

Total PCS $ 694

(1) Other segment items for each segment includes selling, general, administrative, research, and development related expenses, as well as other segment income and expenses.

Significant Expenses by Segment For the three months ended For the year ended

March 31, 2025 June 30, 2025

September 30, 2025

December 31, 2025

AIS:

Cost of sales $ 1,951 $ 2,106 $ 2,218 $ 2,452 $ 8,727

Other segment items(1)

968 932 920 984 3,804

Total AIS

$ 2,919 $ 3,039 $ 3,138 $ 3,436 $ 12,532

PDx:

Cost of sales $ 294 $ 371 $ 384 $ 400 $ 1,450

Other segment items(1)

133 144 145 156 579

Total PDx $ 428 $ 516 $ 529 $ 556 $ 2,028

PCS:

Cost of sales $ 481 $ 507 $ 503 $ 538 $ 2,028

Other segment items(1)

224 212 201 212 849

Total PCS $ 705 $ 719 $ 703 $ 750 $ 2,877

(1) Other segment items for each segment includes selling, general, administrative, research, and development related expenses, as well as other segment income and expenses.

Significant Expenses by Segment For the three months ended For the year ended

March 31, 2024 June 30, 2024 September 30, 2024 December 31, 2024 December 31, 2024

AIS:

Cost of sales $ 1,936 $ 2,004 $ 1,995 $ 2,173 $ 8,108

Other segment items(1)

931 952 932 984 3,798

Total AIS $ 2,867 $ 2,956 $ 2,927 $ 3,157 $ 11,906

PDx:

Cost of sales $ 295 $ 314 $ 312 $ 314 $ 1,236

Other segment items(1)

126 125 120 119 490

Total PDx $ 421 $ 439 $ 432 $ 433 $ 1,725

PCS:

Cost of sales $ 460 $ 480 $ 486 $ 505 $ 1,930

Other segment items(1)

206 215 211 216 848

Total PCS $ 666 $ 694 $ 697 $ 721 $ 2,778

(1) Other segment items for each segment includes selling, general, administrative, research, and development related expenses, as well as other segment income and expenses.

Segment EBIT

For the three months ended

Unaudited

March 31, 2026

Segment EBIT

AIS $ 479

PDx 197

PCS 10

Other(1)

691

Restructuring costs (49)

Acquisition and disposition-related benefits (charges)

(35)

Gain (loss) on business and asset dispositions

—

Spin-Off and separation costs (2)

Amortization of acquisition-related intangible assets (47)

Investment revaluation gain (loss) (8)

Interest and other financial charges – net (96)

Non-operating benefit income (costs) 51

Income before income taxes $ 505

(1) Financial information not presented within the reportable segments, shown within the Other category, primarily represents HFS, which does not meet the definition of an operating segment.

Segment EBIT

For the three months ended For the year ended

Unaudited

March 31, 2025 June 30, 2025 September 30, 2025 December 31, 2025 December 31, 2025

Segment EBIT

AIS $ 460 $ 455 $ 512 $ 641 $ 2,067

PDx 205 213 220 234 872

PCS 48 60 27 74 209

Other(1)

2 1 2 2 7

715 729 761 950 3,155

Restructuring costs (22) (18) (31) (48) (120)

Acquisition and disposition-related benefits (charges)

(8) (7) (9) (15) (39)

Gain (loss) on business and asset dispositions

10 (5) — — 5

Spin-Off and separation costs (24) (5) (6) (3) (38)

Amortization of acquisition-related intangible assets (35) (40) (41) (41) (156)

Investment revaluation gain (loss) 92 (1) 4 16 112

Interest and other financial charges – net (110) (113) (111) (105) (440)

Non-operating benefit income (costs) 74 73 75 66 288

Income before income taxes $ 692 $ 613 $ 643 $ 820 $ 2,768

(1) Financial information not presented within the reportable segments, shown within the Other category, primarily represents HFS, which does not meet the definition of an operating segment.

Segment EBIT For the three months ended For the year ended

Unaudited March 31, 2024 June 30, 2024 September 30, 2024 December 31, 2024 December 31, 2024

Segment EBIT

AIS $ 422 $ 463 $ 518 $ 676 $ 2,080

PDx 178 200 193 212 783

PCS 81 78 82 106 347

Other(1)

(1) 1 1 — 2

681 742 795 994 3,211

Restructuring costs (40) (29) (22) (30) (120)

Acquisition and disposition-related benefits (charges)

— 3 4 (9) (3)

Gain (loss) on business and asset dispositions

— — (1) — —

Spin-Off and separation costs (60) (67) (56) (68) (251)

Amortization of acquisition-related intangible assets (31) (35) (34) (36) (137)

Investment revaluation gain (loss) (20) (6) (1) 4 (22)

Interest and other financial charges – net (122) (131) (130) (121) (504)

Non-operating benefit income (costs) 102 101 102 100 406

Income before income taxes $ 512 $ 578 $ 658 $ 834 $ 2,581

(1) Financial information not presented within the reportable segments, shown within the Other category, primarily represents HFS, which does not meet the definition of an operating segment.

Depreciation and Amortization by Segment

For the three months ended

March 31, 2026

AIS

$ 72

PDx 20

PCS 13

Depreciation and Amortization by Segment

For the three months ended For the year ended

March 31, 2025 June 30, 2025

September 30, 2025

December 31, 2025

AIS

$ 75 $ 75 $ 73 $ 73 $ 297

PDx 12 17 19 19 66

PCS 13 13 14 13 53

Depreciation and Amortization by Segment

For the three months ended For the year ended

March 31, 2024 June 30, 2024 September 30, 2024 December 31, 2024

December 31, 2024

AIS

$ 86 $ 83 $ 82 $ 77 $ 327

PDx 16 15 12 12 55

PCS 15 14 13 14 55

NON-GAAP FINANCIAL MEASURES

The non-GAAP financial measures presented in this Exhibit 99 are supplemental measures of our performance that we believe will help investors understand our results of operations, and assess our future prospects. When read in conjunction with our U.S. GAAP results, these non-GAAP financial measures provide a baseline for analyzing trends in our underlying businesses and can be used by management as one basis for making financial, operational, and planning decisions.

We report Organic revenue and Organic revenue growth rate to provide management and investors with additional understanding and visibility into the underlying revenue trends of our established, ongoing operations, as well as provide insights into overall demand for our products and services. To calculate these measures, we exclude the effect of acquisitions, dispositions, and foreign currency rate fluctuations.

Organic Revenue*

For the three months ended March 31

Unaudited

2026 2025 % change

AIS revenues

$ 3,640 $ 3,379 7.7%

Less: Acquisitions(1)

11 —

Less: Dispositions(2)

— —

Less: Foreign currency exchange

114 —

AIS Organic revenue*

$ 3,515 $ 3,379 4.0%

PDx revenues

$ 770 $ 632 21.7%

Less: Acquisitions(1)

50 1

Less: Dispositions(2)

— —

Less: Foreign currency exchange

28 —

PDx Organic revenue*

$ 692 $ 631 9.7%

PCS revenues

$ 704 $ 753 (6.5)%

Less: Acquisitions(1)

— —

Less: Dispositions(2)

— —

Less: Foreign currency exchange

12 —

PCS Organic revenue*

$ 692 $ 753 (8.1)%

Other revenues

$ 18 $ 13 37.7%

Less: Acquisitions(1)

— —

Less: Dispositions(2)

— —

Less: Foreign currency exchange

— —

Other Organic revenue*

$ 18 $ 13 37.7%

Total revenues

$ 5,131 $ 4,777 7.4%

Less: Acquisitions(1)

60 1

Less: Dispositions(2)

— —

Less: Foreign currency exchange

155 —

Organic revenue*

$ 4,916 $ 4,776 2.9%

(1)

Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction, excluding the impact of Foreign currency exchange already captured in lines elsewhere.

(2)

Represents revenues attributable to dispositions for the four quarters preceding the disposition date.

____________________

*Non-GAAP Financial Measure

Organic Revenue*

For the three months ended December 31 For the year ended December 31

Unaudited

2025 2024 % change 2025 2024 % change

AIS revenues

$ 4,077 $ 3,833 6.4% $ 14,599 $ 13,986 4.4%

Less: Acquisitions(1)

1 — 15 —

Less: Dispositions(2)

— — — —

Less: Foreign currency exchange

56 — 65 —

AIS Organic revenue*

$ 4,020 $ 3,833 4.9% $ 14,519 $ 13,986 3.8%

PDx revenues

$ 790 $ 646 22.3% $ 2,900 $ 2,508 15.6%

Less: Acquisitions(1)

51 1 154 4

Less: Dispositions(2)

— — — —

Less: Foreign currency exchange

13 — 21 —

PDx Organic revenue*

$ 726 $ 645 12.7% $ 2,724 $ 2,504 8.8%

PCS revenues

$ 825 $ 827 (0.3)% $ 3,086 $ 3,125 (1.2)%

Less: Acquisitions(1)

— — — —

Less: Dispositions(2)

— — — —

Less: Foreign currency exchange

7 — 7 —

PCS Organic revenue*

$ 818 $ 827 (1.1)% $ 3,079 $ 3,125 (1.5)%

Other revenues

$ 7 $ 13 (48.1)% $ 40 $ 52 (23.0)%

Less: Acquisitions(1)

— — — —

Less: Dispositions(2)

— — — —

Less: Foreign currency exchange

— — — —

Other Organic revenue*

$ 7 $ 13 (48.1)% $ 40 $ 52 (23.3)%

Total revenues

$ 5,698 $ 5,319 7.1% $ 20,625 $ 19,672 4.8%

Less: Acquisitions(1)

52 1 169 4

Less: Dispositions(2)

— — — —

Less: Foreign currency exchange

75 — 94 —

Organic revenue*

$ 5,571 $ 5,318 4.8% $ 20,363 $ 19,667 3.5%

(1)

Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction.

(2)

Represents revenues attributable to dispositions for the four quarters preceding the disposition date.

____________________

*Non-GAAP Financial Measure

Organic Revenue*

For the three months ended September 30

Unaudited

2025 2024 % change

AIS revenues

$ 3,649 $ 3,445 5.9%

Less: Acquisitions(1)

— —

Less: Dispositions(2)

— —

Less: Foreign currency exchange

41 —

AIS Organic revenue*

$ 3,608 $ 3,445 4.7%

PDx revenues

$ 749 $ 625 19.8%

Less: Acquisitions(1)

51 1

Less: Dispositions(2)

— —

Less: Foreign currency exchange

15 —

PDx Organic revenue*

$ 683 $ 623 9.6%

PCS revenues

$ 731 $ 779 (6.2)%

Less: Acquisitions(1)

— —

Less: Dispositions(2)

— —

Less: Foreign currency exchange

4 —

PCS Organic revenue*

$ 727 $ 779 (6.7)%

Other revenues

$ 15 $ 15 (1.5)%

Less: Acquisitions(1)

— —

Less: Dispositions(2)

— —

Less: Foreign currency exchange

— —

Other Organic revenue*

$ 14 $ 15 (3.1)%

Total revenues

$ 5,143 $ 4,863 5.8%

Less: Acquisitions(1)

51 1

Less: Dispositions(2)

— —

Less: Foreign currency exchange

60 —

Organic revenue*

$ 5,033 $ 4,862 3.5%

(1)

Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction.

(2)

Represents revenues attributable to dispositions for the four quarters preceding the disposition date.

____________________

*Non-GAAP Financial Measure

Organic Revenue*

For the three months ended June 30

Unaudited

2025 2024 % change

AIS revenues

$ 3,493 $ 3,419 2.2%

Less: Acquisitions(1)

— —

Less: Dispositions(2)

— —

Less: Foreign currency exchange

25 —

AIS Organic revenue*

$ 3,468 $ 3,419 1.4%

PDx revenues

$ 729 $ 639 14.1%

Less: Acquisitions(1)

53 2

Less: Dispositions(2)

— —

Less: Foreign currency exchange

7 —

PDx Organic revenue*

$ 669 $ 637 5.0%

PCS revenues

$ 778 $ 772 0.8%

Less: Acquisitions(1)

— —

Less: Dispositions(2)

— —

Less: Foreign currency exchange

3 —

PCS Organic revenue*

$ 775 $ 772 0.4%

Other revenues

$ 6 $ 9 (39.2)%

Less: Acquisitions(1)

— —

Less: Dispositions(2)

— —

Less: Foreign currency exchange

— —

Other Organic revenue*

$ 6 $ 9 (40.6)%

Total revenues

$ 5,007 $ 4,839 3.5%

Less: Acquisitions(1)

53 2

Less: Dispositions(2)

— —

Less: Foreign currency exchange

36 —

Organic revenue*

$ 4,917 $ 4,837 1.7%

(1)

Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction.

(2)

Represents revenues attributable to dispositions for the four quarters preceding the disposition date.

____________________

*Non-GAAP Financial Measure

Organic Revenue*

For the three months ended March 31

Unaudited

2025 2024 % change

AIS revenues

$ 3,379 $ 3,289 2.7%

Less: Acquisitions(1)

14 —

Less: Dispositions(2)

— —

Less: Foreign currency exchange

(57) —

AIS Organic revenue*

$ 3,423 $ 3,289 4.1%

PDx revenues

$ 632 $ 599 5.6%

Less: Acquisitions(1)

— —

Less: Dispositions(2)

— —

Less: Foreign currency exchange

(14) —

PDx Organic revenue*

$ 646 $ 599 7.9%

PCS revenues

$ 753 $ 747 0.8%

Less: Acquisitions(1)

— —

Less: Dispositions(2)

— —

Less: Foreign currency exchange

(7) —

PCS Organic revenue*

$ 760 $ 747 1.7%

Other revenues

$ 13 $ 15 (11.4)%

Less: Acquisitions(1)

— —

Less: Dispositions(2)

— —

Less: Foreign currency exchange

— —

Other Organic revenue*

$ 13 $ 15 (10.0)%

Total revenues

$ 4,777 $ 4,650 2.7%

Less: Acquisitions(1)

14 —

Less: Dispositions(2)

— —

Less: Foreign currency exchange

(78) —

Organic revenue*

$ 4,842 $ 4,650 4.1%

(1)

Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction.

(2)

Represents revenues attributable to dispositions for the four quarters preceding the disposition date.

____________________

*Non-GAAP Financial Measure

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover Page

Jul. 29, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Jul. 29, 2026

Entity Registrant Name

GE HEALTHCARE TECHNOLOGIES INC.

Entity Central Index Key

0001932393

Amendment Flag

false

Entity Incorporation, State or Country Code

Entity File Number

001-41528

Entity Tax Identification Number

88-2515116

Entity Address, Address Line One

500 W. Monroe Street

Entity Address, City or Town

Chicago

Entity Address, State or Province

Entity Address, Postal Zip Code

60661

City Area Code

833

Local Phone Number

735-1139

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, par value $0.01 per share

Trading Symbol

GEHC

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration